Apex Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Apex Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$17.9M	Buy	1,937,344 +827,272	+75%	+$8.9M	0.39%	75
2015 Q4	$16.5M	Buy	1,110,072 +13,315	+1%	+$223K	0.37%	78
2015 Q3	$18M	Buy	1,096,757 +48,691	+5%	+$997K	0.41%	74
2015 Q2	$23.9M	Buy	1,048,066 +67,996	+7%	+$1.35M	0.51%	71
2015 Q1	$14.9M	Buy	980,070 +198,253	+25%	+$2.58M	0.35%	77
2014 Q4	$9.41M	Sell	781,817 -49,274	-6%	-$563K	0.25%	83
2014 Q3	$9.43M	Buy	831,091 +49,440	+6%	+$564K	0.28%	78
2014 Q2	$9.44M	Buy	781,651 +83,937	+12%	+$991K	0.29%	79
2014 Q1	$8.13M	Buy	697,714 +94,558	+16%	+$1.6M	0.29%	80
2013 Q4	$10.7M	Buy	+603,156	New	+$10.1M	0.4%	75

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Apex Capital Management's MNTA Position: Q1 2016 in Review

Apex Capital Management increased its Momenta Pharmaceuticals, Inc. (MNTA) stake by 75% in Q1 2016, buying an estimated $8.9M and bringing the position to 1,937,344 shares worth $17.9M. The position accounts for 0.39% of the portfolio, ranked #75.

Apex Capital Management first reported a position in MNTA in Q4 2013 and has held it in 10 quarters since. The position peaked at $23.9M in Q2 2015. 148 funds tracked by Wall St. Rank hold MNTA as of Q1 2016.

Apex Capital Management held 1,937,344 shares of Momenta Pharmaceuticals, Inc. worth $17.9M as of Q1 2016.
Apex Capital Management bought 827,272 Momenta Pharmaceuticals, Inc. shares in Q1 2016, an estimated $8.9M.
Momenta Pharmaceuticals, Inc. made up 0.39% of Apex Capital Management's portfolio in Q1 2016, its #75 holding.
Apex Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2013 and has held it in 10 quarters since.
Apex Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $23.9M in Q2 2015.
148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.